Dyslipidemia is an abnormal level of lipids (fats) in your blood. That includes cholesterol, triglycerides, or both being too high or too low. It’s one of the most common risk factors for heart disease and stroke, and most people who have it don’t feel any different. The condition is typically caught through a routine blood test called a lipid panel.
What Counts as Abnormal
Your lipid panel measures several types of blood fats, and each one tells a different part of the story. LDL cholesterol, often called “bad” cholesterol, is the number most closely tied to heart disease risk. For people without existing heart disease, an LDL below 130 mg/dL is considered acceptable at low risk, but targets drop sharply as risk rises: below 100 mg/dL for high-risk individuals and below 55 mg/dL for those at extremely high risk, such as people who’ve already had a heart attack or stroke.
HDL cholesterol works in the opposite direction. Higher levels are protective, and low HDL is a concern. Triglycerides, the other major blood fat, are considered elevated at 150 mg/dL or above and severely elevated at 500 mg/dL or higher. That severe range carries its own distinct danger beyond heart disease: it significantly increases the risk of acute pancreatitis, a painful and potentially life-threatening inflammation of the pancreas. The risk of pancreatitis climbs linearly once triglycerides exceed about 177 mg/dL and becomes especially serious above 1,000 mg/dL.
How It Damages Your Arteries
Dyslipidemia doesn’t cause symptoms on its own, but over years it quietly drives atherosclerosis, the buildup of plaque inside artery walls. The process starts when LDL particles penetrate the inner lining of blood vessels and become chemically modified. These modified particles trigger an inflammatory chain reaction. They stimulate the vessel lining to produce inflammatory signals, attract immune cells called monocytes into the artery wall, and reduce the artery’s ability to relax and widen normally.
Once inside the artery wall, monocytes transform into larger immune cells that swallow the modified LDL and become bloated “foam cells.” These foam cells accumulate into fatty streaks, the earliest visible stage of plaque. Over time, smooth muscle cells migrate into the area and the plaque hardens, narrowing the artery. If a plaque ruptures, it can trigger a blood clot that blocks blood flow entirely, causing a heart attack or stroke.
Primary Causes: Genetics
Some people develop dyslipidemia because of inherited gene mutations that disrupt how the body processes fats. These genetic forms, called primary dyslipidemia, can produce dangerously high lipid levels even in childhood.
Familial hypercholesterolemia is the most well-known example. It’s caused by mutations in the gene for the LDL receptor, the protein on liver cells responsible for pulling LDL out of the bloodstream. With fewer working receptors, LDL accumulates to very high levels and accelerates atherosclerosis decades earlier than usual. Under the diagnostic criteria used in the U.S. (the MEDPED system), a child under 18 with a first-degree relative who has the condition may be flagged with total cholesterol as low as 220 mg/dL, while someone over 40 from the general population would need levels above 360 mg/dL to meet the same diagnostic threshold.
Other inherited forms include familial hypertriglyceridemia, where mutations impair the body’s ability to break down triglycerides, leading to extremely high triglyceride levels and pancreatitis risk. Familial combined hyperlipidemia causes the liver to overproduce certain fat-carrying particles, raising both cholesterol and triglycerides simultaneously.
Secondary Causes: Lifestyle and Other Conditions
Far more commonly, dyslipidemia develops from a combination of lifestyle factors and other medical conditions. Physical inactivity, a diet high in saturated fat, obesity, smoking, and heavy alcohol use all shift lipid levels in unfavorable directions.
Several chronic diseases also cause or worsen dyslipidemia. Diabetes is a major driver: insulin resistance impairs the body’s ability to break down triglycerides and clear LDL from the blood, typically producing high triglycerides, high LDL, and low HDL all at once. Hypothyroidism reduces the number of LDL receptors on liver cells and slows triglyceride clearance, pushing both numbers up. Chronic kidney disease impairs the breakdown of fat-carrying particles in the blood, creating a similar pattern of high triglycerides, high LDL, and low HDL. Liver disease and certain medications can also alter lipid levels significantly.
Visible Signs of Severe Dyslipidemia
Most people with dyslipidemia have no outward signs, which is why screening matters. But in severe or long-standing cases, cholesterol deposits can appear on the body. Xanthelasmas are yellowish, flat or slightly raised growths that develop on or near the eyelids, typically at the corners closest to the nose. They can be soft, firm, or chalky in texture. While harmless on their own, they signal that lipid levels may be substantially elevated.
Tendon xanthomas are firmer deposits that form along tendons, particularly the Achilles tendon and tendons on the backs of the hands. A white or gray ring around the edge of the cornea (called corneal arcus), especially in someone under 45, is another physical clue. These signs are strongly associated with familial hypercholesterolemia and are even used as part of formal diagnostic scoring systems in the U.K. and the Netherlands.
When and How It’s Detected
Dyslipidemia is diagnosed with a simple blood draw. The standard lipid panel reports total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Guidelines from the American College of Cardiology and American Heart Association recommend assessing cardiovascular risk factors, including lipids, every four to six years starting at age 20. The older ATP III guidelines recommend a full lipid panel every five years beginning at age 20. For men aged 35 and older and women aged 45 and older who have cardiovascular risk factors, the U.S. Preventive Services Task Force supports routine screening more strongly.
Your results are interpreted alongside other risk factors like age, blood pressure, smoking status, diabetes, and family history, not in isolation. Two people with the same LDL number can have very different treatment targets depending on their overall risk profile.
Dietary and Lifestyle Changes
For many people, particularly those with mildly to moderately elevated lipids, lifestyle changes are the first line of management. Increasing soluble fiber intake is one of the most evidence-backed dietary strategies. Eating 5 to 10 grams of soluble fiber per day can lower total and LDL cholesterol by 5 to 11 points, sometimes more. Practical sources include oatmeal, beans, lentils, flaxseed, berries, pears, broccoli, carrots, and cabbage. A day that includes oatmeal with berries and ground flax at breakfast, a bean-based chili with a pear at lunch, carrots with hummus as a snack, and steamed vegetables at dinner gets you to about 10 grams.
Reducing saturated fat intake, increasing physical activity, losing excess weight, and quitting smoking all independently improve lipid levels. These changes also improve insulin sensitivity, blood pressure, and inflammation, compounding their benefit beyond what the lipid numbers alone suggest.
Medications for Dyslipidemia
When lifestyle changes aren’t enough, or when cardiovascular risk is high enough to warrant immediate treatment, medications become part of the plan. Statins remain the cornerstone. They work by blocking an enzyme in the liver that’s essential for cholesterol production. With less cholesterol being made internally, liver cells respond by pulling more LDL out of the bloodstream, lowering circulating levels. Low-intensity statin therapy reduces LDL by up to 30%, while high-intensity therapy cuts it by more than 50%.
For people who can’t tolerate statins or who need additional LDL lowering on top of a statin, newer options exist. PCSK9 inhibitors are injectable medications given every two to four weeks. They work by preventing the breakdown of LDL receptors on liver cells, keeping more receptors available to clear LDL from the blood. These drugs are powerful: one can reduce LDL by up to 72%, the other by up to 65%.
Bempedoic acid is an oral option that blocks cholesterol production through a different pathway than statins. It’s particularly useful for people who experience muscle pain on statins, since it’s active only in the liver and doesn’t affect muscle tissue. Its maximum LDL reduction is more modest, around 28% when used alone. For severely elevated triglycerides above 500 mg/dL, where the primary concern is pancreatitis rather than cholesterol, fibrates and omega-3 fatty acid preparations are the typical medications used to bring levels down.
Why Target Numbers Vary by Person
There’s no single “normal” cholesterol number that applies to everyone. Treatment targets are risk-stratified. Someone with no risk factors might simply aim to keep LDL below 130 mg/dL. A person with diabetes and high blood pressure might need to get below 70 mg/dL. Someone who’s already had a heart attack or stroke is typically managed to below 55 mg/dL. The corresponding targets for non-HDL cholesterol (which captures a broader picture of harmful lipids) run about 30 mg/dL higher than the LDL targets at each risk level.
This is why two people can look at the same lipid panel result and get completely different advice. The lipid numbers are one input into a broader risk calculation, and the aggressiveness of treatment scales with overall cardiovascular risk, not with any single lab value.